title: The global challenge of new classes of antibacterial agents: an industry perspective.
abstract: With rising antibiotic resistance and the fear of returning to the pre-penicillin era, incentives are being provided for developing novel antibiotics. The hurdles faced by antibiotic developers include the difficulty in discovering novel chemicals that have selectivity and the increased regulatory scrutiny for safety and efficacy. Furthermore, the demonstration of superiority is essential in order to rationalize pricing and to assure a return on investment. Suggestions are provided to overcome each of these hurdles in order to prevent the antibiotic pipeline from running dry.
authors.affiliation: Cempra, Inc., Building Two, 6320 Quadrangle Drive, Suite 360, Chapel Hill, NC 27517, USA. Electronic address: prabha@fernandes-domain.com.
authors.forename: Prabhavathi
authors.initials: P
authors.lastname: Fernandes
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents; D017277:Drug Approval; D055808:Drug Discovery; D004345:Drug Industry; D024881:Drug Resistance, Bacterial; D006801:Humans; D009042:Motivation
chemical_list: D000900:Anti-Bacterial Agents